Tag Archives: Family Office

Hot Investor Mandate 1: West Coast-Based Family Office Invests Up to $10M Into Early-Stage Therapeutics, Devices, and Tools Companies

31 May

A family office based in the West Coast invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Family Office with USA and UK Offices Seeks to Invest Up to $5M in Early-Stage Therapeutics Companies with Preference for Platform Technologies

24 May

A family office investment vehicle with offices in the USA and UK is looking to provide equity capital to USA-based therapeutic companies. The firm usually invests in Series A or B rounds, and will consider to participate in a seed round of financing. The firms typical deal size is variable, generally going as high as $5 million for an initial investment.

The firm is currently looking for companies developing Therapeutics. The firm is opportunistic in terms of sub-sector and indication though they do have a preference for companies with platform technologies. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials. The firm’s portfolio includes oncology, the microbiome, pain, neurological and rare diseases biotech companies.

The firm looks to invest in companies with experienced management teams. The firm is capable to act as either a lead or a co-lead investor and generally seeks board or board observer rights. As a pro-active investor, the firm will assist in the growth of a company, recruit new talents, develop preclinical, clinical and IP strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Firm Partnered with a Family Office Seeking to Provide Seed Capital to USA-Based Therapeutics Opportunities

17 May

A Chicago-based life sciences investment fund is focused on accelerating the growth of early-stage biotechnology and pharmaceutical companies. Partnered with a family investment office, the firm seeks to make 10 seed round investments within the next year. The firm will invest in companies based in the U.S.

The firm is seeking investments in biotech/therapeutics companies and is not interested in medical device or digital health technologies. The firm is interested in companies with assets or platform technologies in preclinical or early clinical development and is indication agnostic.

The firm does not have any company management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Toronto-Based Single Family Office Looking to Invest in Seed-Stage Medtech, Diagnostics, and Digital Health Companies

3 May

A single family office based in Toronto, Ontario has its main focus on real estate and mining, but is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space. The firm may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Newly Founded Family Office Actively Seeking Early-Stage Life Science Investments, from Pre-Clinical Stage Assets to Medical Devices

15 Mar

A newly formed Delaware family office investment vehicle representing East Coast-based family interests is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing in companies located throughout North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Device and Diagnostics Sectors that address underserved medical needs, or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis and are especially interested in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell- based therapeutics.

The firm is less interested in small molecules and generally will not consider biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease- modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency.

For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Biotech Family Offices Discuss Direct Investment at RESI Boston

24 Aug

By Lucy Parkinson, Director of Research, LSN

RESI Partnering is now open, providing attendees with the opportunity to book one on one meetings with investors.  If you log in to Partnering, you will see a wide variety of investors available to reach out to, including venture capital firms, big pharma, angels – and family offices.

RESI Boston’s Biotech Family Office sesssion features family office investors from around the world who are making direct investments into early stage drug development companies.  These firms have a variety of strategies, interests and motivations.  If you’d like to know how family office investors think about early stage drugs and what kind of technology catches their eye, this is the panel for you.

Moderated by Colin Widen (CEO, Boston Innovation Capital), the panelists are:

  • Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
  • Pini Orbach (Head of Pharma, Arkin Bioventures)
  • Alex Pickett (Principal, Mediqventures)
  • Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital)

We’ve extended the RESI discounted registration until Friday, so if you want to hear from these Biotech Family Offices now is the time to get registered.

%d bloggers like this: